AROLDI, ANDREA
 Distribuzione geografica
Continente #
NA - Nord America 4.995
AS - Asia 3.225
EU - Europa 2.455
SA - Sud America 475
Continente sconosciuto - Info sul continente non disponibili 136
AF - Africa 85
OC - Oceania 11
Totale 11.382
Nazione #
US - Stati Uniti d'America 4.715
IT - Italia 1.160
VN - Vietnam 913
SG - Singapore 852
CN - Cina 600
BR - Brasile 354
HK - Hong Kong 310
RU - Federazione Russa 270
DE - Germania 233
CA - Canada 164
SE - Svezia 141
IE - Irlanda 134
BD - Bangladesh 116
GB - Regno Unito 101
FR - Francia 95
IN - India 87
KR - Corea 58
ES - Italia 57
FI - Finlandia 50
AR - Argentina 45
PL - Polonia 45
NL - Olanda 44
ID - Indonesia 39
MX - Messico 38
ZA - Sudafrica 35
IQ - Iraq 34
JP - Giappone 30
TR - Turchia 30
CH - Svizzera 26
PH - Filippine 25
PK - Pakistan 22
AT - Austria 21
SA - Arabia Saudita 19
UA - Ucraina 19
CO - Colombia 18
VE - Venezuela 18
CR - Costa Rica 15
UZ - Uzbekistan 15
EC - Ecuador 13
HN - Honduras 13
EG - Egitto 11
GT - Guatemala 11
LT - Lituania 10
CZ - Repubblica Ceca 9
PT - Portogallo 9
AU - Australia 8
CL - Cile 8
IL - Israele 8
KE - Kenya 8
AE - Emirati Arabi Uniti 7
ET - Etiopia 7
JM - Giamaica 7
PY - Paraguay 7
IR - Iran 6
MA - Marocco 6
DO - Repubblica Dominicana 5
NO - Norvegia 5
NP - Nepal 5
PR - Porto Rico 5
RO - Romania 5
SV - El Salvador 5
TT - Trinidad e Tobago 5
AZ - Azerbaigian 4
KG - Kirghizistan 4
KZ - Kazakistan 4
MY - Malesia 4
PE - Perù 4
TH - Thailandia 4
UY - Uruguay 4
AM - Armenia 3
BG - Bulgaria 3
BO - Bolivia 3
CY - Cipro 3
GR - Grecia 3
JO - Giordania 3
MU - Mauritius 3
NI - Nicaragua 3
RS - Serbia 3
AO - Angola 2
BB - Barbados 2
BH - Bahrain 2
CI - Costa d'Avorio 2
DK - Danimarca 2
DZ - Algeria 2
HR - Croazia 2
LA - Repubblica Popolare Democratica del Laos 2
LB - Libano 2
MM - Myanmar 2
MT - Malta 2
NG - Nigeria 2
NZ - Nuova Zelanda 2
PA - Panama 2
PS - Palestinian Territory 2
QA - Qatar 2
SC - Seychelles 2
TN - Tunisia 2
TW - Taiwan 2
XK - ???statistics.table.value.countryCode.XK??? 2
ZW - Zimbabwe 2
AG - Antigua e Barbuda 1
Totale 11.229
Città #
Ashburn 554
Ann Arbor 545
Singapore 476
San Jose 418
Milan 381
Ho Chi Minh City 279
Hong Kong 279
Hanoi 255
Dallas 218
Los Angeles 183
New York 154
Council Bluffs 146
Dublin 134
Frankfurt am Main 131
Hefei 119
Beijing 90
Chandler 86
Santa Clara 84
Toronto 84
Chicago 76
Fairfield 71
Wilmington 70
Woodbridge 65
Columbus 60
Rome 59
Seoul 56
Houston 53
Phoenix 45
Seattle 41
The Dalles 40
Buffalo 39
Lauterbourg 39
São Paulo 39
Boardman 36
Haiphong 34
Staranzano 34
Montreal 32
Shanghai 32
Atlanta 30
Jakarta 30
Munich 30
Warsaw 30
Johannesburg 27
Turin 27
Kent 26
Orem 26
Tokyo 26
Princeton 24
Biên Hòa 22
Poplar 21
Cambridge 20
Helsinki 20
Monza 20
Zurich 20
Brooklyn 19
Lissone 19
London 19
Moscow 19
Da Nang 18
Chennai 17
Guangzhou 17
Nuremberg 17
Thái Nguyên 17
Turku 17
Desio 16
Ha Long 16
Hải Dương 16
Sesto San Giovanni 16
Baghdad 15
Denver 15
Ninh Bình 15
Figino 14
Rio de Janeiro 14
Romola 14
Stockholm 14
Amsterdam 13
Lawrence 13
Naples 13
Seveso 13
Bologna 12
Jacksonville 12
Quận Bình Thạnh 12
Salt Lake City 12
San José 12
Tashkent 12
Altamura 11
Bắc Ninh 11
Charlotte 11
Lappeenranta 11
Washington 11
Can Tho 10
Guatemala City 10
Mexico City 10
Newburgh 10
Philadelphia 10
Riyadh 10
Bogotá 9
Curitiba 9
Dhaka 9
Genoa 9
Totale 6.555
Nome #
Evaluating the performance of large language models in haematopoietic stem cell transplantation decision-making 511
Real-world collection of secondary myeloid neoplasms after CD19 CAR-T cell therapy: first report of the ClonHema study 456
Idiopathic erythrocytosis: a germline disease? 428
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis 428
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia 420
Integrative multi-omics analysis enables a comprehensive characterization of prostate cancer and unveils metastasis-associated candidate biomarkers 405
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy 399
Anaplastic Lymphoma Kinase (ALK) Inhibitors Enhance Phagocytosis Induced by CD47 Blockade in Sensitive and Resistant ALK-Driven Malignancies 377
Case Report: Successful use of emapalumab in adult B-cell acute lymphoblastic leukemia experiencing severe neurotoxicity and hemophagocytic lymphohistiocytosis-like features after CAR-T cell therapy 363
Characterization of SARS-CoV-2 Mutational Signatures from 1.5+ Million Raw Sequencing Samples 362
Evolutionary signatures of human cancers revealed via genomic analysis of over 35,000 patients 355
Integrated Genomic, Functional and Prognostic Characterization of Atypical Chronic Myeloid Leukemia (aCML) in a Cohort of 43 Patients 355
Chronic myeloid leukemia: Second-line drugs of choice 353
Hb Monza: A novel extensive HBB duplication with preserved α-β subunit interaction and unstable hemoglobin phenotype 335
Prognostic Biomarkers in Breast Cancer via Multi-Omics Clustering Analysis 331
Comprehensive analysis of mutational processes across 20 000 adult and pediatric tumors 322
Neurological symptoms in essential thrombocythemia: Impact of JAK2V617F mutation and response to therapy 315
Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors 300
Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea 297
Effects of blocking CD24 and CD47 'don't eat me' signals in combination with rituximab in mantle-cell lymphoma and chronic lymphocytic leukaemia 294
Humoral and cellular immune response in patients with hematological disorders after two doses of BNT162b2 mRNA COVID-19 vaccine: A single-center prospective observational study (NCT05074706) 284
Iron chelation therapy with deferasirox in the management of iron overload in primary myelofibrosis 274
Validation of a new NGS-based myeloid panel in acute myeloid leukemia: A single-center experience 267
First-Hit SETBP1 Mutations Cause a Myeloproliferative Disorder with Bone Marrow Fibrosis Mimicking Triple Negative Myelofibrosis 264
Deferasirox in the management of iron-overload in patients with myelofibrosis: a multicentre study from the Rete Ematologica Lombarda (IRON-M study) 260
Integrative analysis of KEAP1/NFE2L2 alterations across 3600+ tumors reveals an NRF2 expression signature as a prognostic biomarker in cancer 258
Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success 253
First-Hit SETBP1 Mutations Cause a Myeloproliferative Disorder with Bone Marrow Fibrosis 251
Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019 251
A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK+ lymphomas 244
Post-Transplant Lymphoproliferative Disease (PTLD) after Allogeneic Hematopoietic Stem Cell Transplantation: Biology and Treatment Options 227
Transfusion of blood products derived from SARS-CoV-2+ donors to patients with hematological malignancies 206
ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells 188
Author Correction: Integrative analysis of KEAP1/NFE2L2 alterations across 3600+ tumors reveals an NRF2 expression signature as a prognostic biomarker in cancer (npj Precision Oncology, (2025), 9, 1, (291), 10.1038/s41698-025-01088-0) 178
Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia 164
Palbociclib targets β-catenin for degradation and synergizes with KRAS or ERK5 inhibition in colorectal cancer preclinical models 145
Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors 139
Prognostic Score for Myelodysplastic Syndromes Based on Molecular Evolution 123
Totale 11.382
Categoria #
all - tutte 32.911
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 32.911


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022159 0 0 0 38 14 23 4 8 7 10 17 38
2022/2023421 37 117 37 27 24 62 29 8 35 12 26 7
2023/2024650 14 20 30 27 61 175 96 25 67 42 26 67
2024/20251.883 56 141 88 76 119 88 113 69 170 323 213 427
2025/20265.590 887 456 456 708 495 222 769 223 340 462 224 348
2026/20271.700 314 299 488 599 0 0 0 0 0 0 0 0
Totale 11.382